PharmaTher
Develops and commercializes personalized peptide therapeutics using 3D printing (paste extrusion) and AI, with a focus on point-of-care manufacturing for compounded peptides.
- CEO / Founder
- Fabio Chianelli
- Team Size
- 11-50
- Stage
- Early Stage
- Total Funding
- $7.9M
- Latest Round
- Post-IPO
Technology & Products
Key Products
Personaliz3D Peptides; MEDBOTX (robotic 3D printing platform); CraftMake (evaluation platform)
Technological Advantage
Proprietary paste extrusion process for pharmaceuticals, GMP-ready platform (CraftMake Production Plus) with enclosed environment and dual printheads. Advantage is protectable via trade secrets and patents; process is replicable by well-funded competitors but first-mover in peptide compounding.
Differentiation
Value Proposition
Enables personalized dosing, controlled-release profiles, and multi-drug combinations via 3D printing, addressing limitations of conventional tableting for small-batch, complex-geometry production.
How They Differentiate
Focus on peptide therapeutics and paste extrusion at room temperature, vs. powder-bed or vat photopolymerization used by competitors; targets compounded peptides rather than mass-produced tablets.
Market & Competition
Target Customers
Pharmacies, compounding centers, patients requiring personalized peptide doses
Industry Verticals
Pharmaceuticals; Personalized Medicine; Compounding
Competitors
Aprecia Pharmaceuticals (ZipDose); Triastek (3D printed tablets); FabRx (3D printing for pharmaceuticals)
Growth & Milestones
Major Milestones
Launched Personaliz3D Peptides division (2026); Partnered with Craft Health to evaluate CraftMake platform (2026); FDA approval for KETARx (ketamine) (2025)